Progress in diagnosis and treatment of difficult-to-treat asthma in children

Ther Adv Respir Dis. 2023 Jan-Dec:17:17534666231213637. doi: 10.1177/17534666231213637.

Abstract

At present, medications containing inhaled corticosteroids (ICS-containing) are the keystones of asthma treatment. The majority of asthmatic children can significantly improve clinical outcomes with little worsening by standardized inhaled glucocorticoid treatment, but there is still a small proportion of children who are unable to achieve good symptom control even after the maximum standardized treatment, known as 'children with difficult-to-treat asthma (DA)'. The high heterogeneity of DA makes therapy challenging and expensive, which poses a serious risk to children's health and makes it extremely difficult for clinical physicians to accurately identify and treat children with DA. This article reviews the definition, evaluation, and treatment of this asthma in order to provide a reference for optimal clinical decision-making.

Keywords: children; diagnosis and evaluation; difficult-to-treat asthma; treatment.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Asthmatic Agents* / adverse effects
  • Asthma* / diagnosis
  • Asthma* / drug therapy
  • Child
  • Drug Therapy, Combination
  • Humans

Substances

  • Anti-Asthmatic Agents
  • Adrenal Cortex Hormones